0.87  0.039 (4.74%)		05-12 16:00
Open: 0.87 High: 0.87 Volume: 159,282		Pre. Close: 0.8306 Low: 0.8358 Market Cap: 33(M)

Short term
Mid term
Targets	6-month :	1.44	1-year :	1.78
Resists	First :	1.23	Second :	1.52
Pivot price	1.04
Supports	First :	0.76	Second :	0.63
MAs	MA(5) :	0.86	MA(20) :	1.06
	MA(100) :	1.38	MA(250) :	3.13
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	6.3	D(3) :	5.2
RSI	RSI(14): 40.3
52-week	High :	13.59	Low :	0.76

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ FBLG ] has closed above bottom band by 22.5%. Bollinger Bands are 13.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.89 - 0.9	0.9 - 0.91
Low:	0.78 - 0.78	0.78 - 0.79
Close:	0.82 - 0.83	0.83 - 0.84

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Mon, 31 Mar 2025
FibroBiologics Slashes Annual Losses by $5.3M as Key Clinical Trial Approaches - Stock Titan

Sat, 08 Feb 2025
FBLG Stock Price and Chart — NASDAQ:FBLG - TradingView

Mon, 30 Dec 2024
D. Boral Capital Served as Exclusive Placement Agent to - GlobeNewswire

Thu, 14 Nov 2024
Here's Why We're Watching FibroBiologics' (NASDAQ:FBLG) Cash Burn Situation - simplywall.st

Sun, 04 Feb 2024
StockWatch: Alto, Fractyl, FibroBiologics Join Parade of Public Biotechs - Genetic Engineering and Biotechnology News

Wed, 31 Jan 2024
FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	38 (M)
Shares Float	28 (M)
Held by Insiders	21.3 (%)
Held by Institutions	15.6 (%)
Shares Short	1,530 (K)
Shares Short P.Month	2,210 (K)

EPS	-0.35
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.07
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-60.8 %
Return on Equity (ttm)	-559.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.36
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-12 (M)

PE Ratio	-2.56
PEG Ratio	0
Price to Book value	10.87
Price to Sales	0
Price to Cash Flow	-2.8

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.